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Abstract 
Large-scale, low-cost genome analysis has become possible with next-generation sequencing technology, 
which is currently used in research and clinical practice. Many attempts of returning individual genomic 
results have commenced not only in clinical practice, but also in research settings of several countries. In 
Japan, the government guidelines include a section on the disclosure of genetic information regarding 
genome analysis in research. However, no practical guidance for the return of individual genomic results 
in research settings (ROGRR) currently exists. We propose practical guidance regarding ROGRR in Japan 
based on extensive research, including a literature review of related previous studies, an examination of 
the relevant legislation in Japan, and interviews with stakeholders. The guidance we developed consists of 
“Points to consider” and “Issues for further discussion and consideration.” The “Points to consider” were 
divided into five parts, from preliminary review before discussion of policy, to the actual return and 
follow-up process, in the order of the assumed ROGRR process. It is anticipated that a situation will arise 
where numerous research projects will consider ROGRR carefully and realistically in the future, and in the 
process of drafting such practical guidance, various issues requiring continuous discussion will emerge. 
The necessities of continuous discussion concerning ROGRR in Japan’s context is increasing, particularly 
in terms of the ethical, legal, and social implications. We believe such discussions and considerations may 
contribute to creating a new system that will increase availability of personalized medicine and prevention 
using genetic information, allowing them to become useful to the broader population.  
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Introduction 
Large-scale, low-cost genome analysis has become possible with next-generation sequencing 
technology, which is currently used in research and clinical practice. In 2013, the American College of 
Medical Genetics and Genomics published policy statements on the return of incidental findings 
(subsequently revised as “secondary findings”) in clinical exome and genome sequencing (1, 2), which 
prompted widespread and diverse discussion (3-5). There is also growing debate about returning genomic 
research results to participants (6-8). Numerous attempts to return individual genomic results have been 
initiated not only in clinical but also in research settings in several countries (9-12).  
In Japan, the government’s Ethical Guidelines for Human Genome/Gene Analysis Research 
(JEGHG) includes a section on the Disclosure of Genetic Information regarding genome analysis in 
research, which states, “With regard to human genome/gene analysis research through which the genetic 
information of individual donors is obtained, when a donor has requested disclosure of that, the 
researchers shall, in principle, disclose the requested information.”(13) This description reflects the 
importance of participants' right to know their own information, which may have great impact on the 
participants' health. Yet, there is little mention of specific points to consider (13). Although Japanese 
academic society guidelines on clinical genetic testing have been presented (14), no practical guidance on 
the return of individual genomic results in research settings (ROGRR) exists. Nevertheless, with the 
increase of data and knowledge on disease-causing variants, it is likely that researchers will need guidance 
to effectively deal with them. We posit that practical guidance tailored to the current state of affairs in 
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Japan is needed for researchers handling ROGRR. Therefore, this study aims to propose the first Japanese 
practical guidance for ROGRR based on extensive research. 
 
 
Methods 
To understand the current circumstances affiliated with ROGRR, several investigations were 
conducted, including a literature review of previous studies on ROGRR, an examination of the relevant 
legislation in Japan, and interviews with stakeholders. Fifteen researchers and genomics experts were 
interviewed. In some interviews, interviewees’ collaborators participated, increasing the total number of 
interviewees to 20. The researchers interviewed were the principal investigators of the ten themes of the 
Japan Agency for Medical Research and the Development funded Platform Program for Promotion of 
Genome Medicine Advanced Genome R&D, which was selected as the main target for large-scale projects 
on human genome analysis. The five experts other than the researchers were selected purposively for their 
wide range of knowledge of the issues around ROGRR, including medical geneticists, an expert of clinical 
laboratory, and an individual with a genetic condition. All interviews were recorded and with the 
permission of the interviewees, summaries were subsequently created and classified as points of interest. 
Based on these results, we prepared drafts of the practical guidance for ROGRR for stakeholders in Japan 
that consist of “Points to consider” and “Issues for further discussion and consideration,” respectively. 
The drafts of the guidance were also reviewed by the five supervisors of the Japan Agency for Medical 
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Research and the Development’s research project mentioned above. Feedback was requested from 20 
groups including the interviewees. The final version of the guidance and the summery of the 
investigations described above were published on the Japan Agency for Medical Research and the 
Development website in Japanese (15). 
In this paper, we present “Points to consider” as suggestions that provide practical guidance in the 
“Results” section, while the “Discussion” was composed based on “Issues for future discussion and 
consideration,” as well as other content deemed relevant. Before each interview, we asked interviewees 
about recording and summarizing an interview for making drafts of the practical guidance, and verbal 
consent was obtained. Following the completion of this guidance, written informed consent (IC) 
regarding publishing was obtained from all interviewees. This study was approved by the Institutional 
Review Boards of Tohoku Medical Megabank Organization at Tohoku University (2019-4-004) and 
Osaka University (19041). 
 
 
Results 
Preliminary Investigations 
Literature review of previous studies on ROGRR 
A total of 27 published research articles met the criteria and 22 projects were mentioned in those 
articles (Supplementary Table 1). There were 13 projects in the US, one each in the UK, Canada, Sweden, 
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Estonia, Singapore, Germany, Australia, Switzerland, and Japan. Three projects returned results in 
medical research including the use of samples and information in biobanks. Five projects included 
research participants who were ostensibly healthy people. Eleven projects returned secondary findings in 
studies regarding rare diseases or cancer, and three projects were considering ROGRR in the future.  
 
Examination of the relevant legislation in Japan 
We investigated Japanese legislations related to the ROGRR. Major legislation governing the 
return (disclosure) of genomic results include the Act on the Protection of Personal Information and the 
related laws, JEGHG, Ethical Guidelines for Medical and Health Research Involving Human Subjects, 
among others (See Table 1). Under the Act on the Protection of Personal Information, personal 
information (including genomic information) should be disclosed if the concerned person requested, but 
this principle is exempted for research use. The use is regulated by research guidelines such as JEGHG. 
Research that analyzes germline variants requires adherence to the JEGHG, and it is based on the 
principle of disclosure if the concerned person requested, but non-disclosure is permitted in certain cases. 
 
Interviews with stakeholders 
All contacted persons participated in an interview. Interviews were conducted either at their office or in a 
public meeting room, and lasted 30 to 90 minutes. All researchers were engaged with human genome 
analysis research, and had various background, including physicians, molecular or informatics biologists, 
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or researchers belonging to institutes not affiliated with medical institutions. Some researchers responded 
that their project planned to or did ROGRR, and the rest commented that their project could not ROGRR 
for some reasons. Some experts had experiences of ROGRR as researchers. Interview summaries classified 
as points of interest are shown in Table 2, and the detailed results were published as a report on the 
website (15). 
 
Points to Consider: Return of Individual Genomic Results in Research Settings 
Introduction of “points to consider” 
Several “Points to consider” were proposed for the practical guidance for ROGRR. Researchers 
determine the overall policy on ROGRR and proceed with the return process after a thorough 
investigation, which accounts for the characteristics of the genetic information. It is necessary to proceed 
according to the specific characteristics for each research project.  
In a determination of the ROGRR policy of each project, it is required to observe the JEGHG and 
other relevant legislation and guidelines. Moreover, when implementing a return plan, the institutional 
review board of the relevant facility should be consulted and provide approval for said plan prior to its 
implementation.  
This guidance does not recommend actively implementing ROGRR in every research project. 
However, as there may be possibly important findings related to the health and reproduction of research 
participants in the information obtained in research based on genomic analysis, we hoped that attempts of 
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ROGRR in various situations will increase. Hopefully, this guidance will serve as a useful reference for the 
numerous situations that projects may need to consider ROGRR.  
 
Scope of Guidance 
The return of germline genetic information is the primary target within ROGRR based on the 
description in the JEGEG. In addition to the return of primary findings (e.g., results concerning rare 
genetic diseases for patients), which has been carried out for a few decades, this section is concerned with 
the following possible situations in which ROGRR would occur: the return of relevant variant information 
in cases where intervention research (e.g., clinical trials) is conducted using the results of genome analysis, 
the return of genetic information aimed at evaluating the return process and psychosocial facts, and the 
return of secondary findings and incidental findings. New situations could emerge in the future, including 
the return of risk information on multifactorial diseases and returnable secondary findings from 
transcriptome/epigenome analysis. Moreover, given that the context of performing whole genome/exome 
analysis in research differs from clinical genetic testing, it was assumed that there would be situations 
where it would be difficult to clearly classify returnable genetic information into primary, secondary, and 
incidental findings. Therefore, comprehensive references will be provided in this guidance without 
classifying genetic information to return. Furthermore, although it is described as the “disclosure” of 
genetic information in JEGHG, we will use the term “return” in this guidance, as it is assumed that the 
variants related to the target genetic information have been detected and research participants will be 
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informed of the results based on expert interpretation, genetic counseling, and adequate follow up, 
including referrals to medical professionals. 
 
Characteristics of Germline Genetic Information 
Depending on the type of information returned, ROGRR could lead to the genetic testing and 
diagnosis of research participants and their respective biological relatives. Therefore, it is necessary to 
consider the characteristics of genetic information just as carefully as genetic testing and diagnosis in 
clinical practice.  
 
Points to Consider on ROGRR  
We assume that ROGRR consists of the following process: preliminary review before discussion of 
policy on ROGRR, discussion and determination of policy on ROGRR (a non-return policy is a possible 
option at this stage), IC and confirmation of preference for ROGRR, analysis related to information with 
possibility of return, and return of results to research participants who prefer the genetic information. 
Several pertinent points are listed below. Researchers ought to give due consideration to the 
circumstantial variation of each project (e.g., difficulty designing a plan in detail before the onset of 
research and limited participant contact during and after the study), while considering when and how to 
examine the following points. 
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1. Preliminary review before discussion of policy on ROGRR 
When planning research, because the situations around ROGRR related to genetic information 
differ depending on the research purpose and content, it is advisable to review points (1) through (6) 
before designing the plan in detail regarding policy on ROGRR. A summary of this section is shown in 
Figure 1. 
(1) In interventional and observational research based on genetic information, it may be necessary to 
return the relevant genetic information to research participants. Confirm whether the return of 
the results is included in the main research purpose and content as in, for example, 
interventional research using the results of genome analysis to determine the administration of 
medication, or the return of genetic information to evaluate psychosocial factors or verify the 
return process. In applicable cases, proceed to (6), and consider the specific return details and 
methods in accordance with the purpose and content of the research, as well as points required 
by associated laws and guidelines.  
(2) For research other than what was covered in (1), confirm whether the samples and information 
used for analysis are newly acquired in the research or based on the use of pre-existing samples 
and information through the transfer of samples and information or cooperative research. Plans 
in place to acquire new samples and information should proceed to (4).  
(3) Research on pre-existing samples and information ought to carefully consider whether ROGRR 
is possible by checking the original terms of use and contractual content (with the supplier) in 
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the transfer of samples and information or any cooperative research and the accompanying 
consent with respect to the possibility of ROGRR. It should also consider whether it is possible to 
reconnect genomic analysis results with individual information (e.g., contact details), and 
whether it is possible to re-contact research participants regarding ROGRR.  
(4) New research based on the acquisition of original samples and information or the use of 
pre-existing data where ROGRR may be possible should consider whether returnable genetic 
information can be obtained. At this point, if genome-wide analysis (e.g., whole genome/exome 
analysis) is planned, researchers should expect possible ROGRR and examine the feasibility of 
actual return, regardless of whether the research planned to detect variants out of the research 
purpose.  
(5) If returnable genetic information is expected to be obtained in (3), it is important to consider 
whether such research can feasibly secure the necessary financial and human resources for 
ROGRR, including analysis expenses, which may include confirmation testing, and a system that 
can provide genetic counseling.  
(6) After considering points (1) through (5), review the points presented in JEGHG policy 
concerned with determining whether genetic information is accurate and reliable enough to 
assess donor’s health condition, which indicate important facts related to his or her health, and 
whether such disclosure could disrupt the appropriate research procedures.  
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2. Discussion and decision of policy on ROGRR 
1) Framework for the consideration and decision of policy on ROGRR 
 Discuss the policy on ROGRR among researchers on the project, including researchers from 
cooperative research institutions, and in the case of using pre-existing samples and 
information, the supplier of them. 
 It is desirable to reference the opinions of diverse stakeholders, including potential eligible 
research participants and the researchers involved, when discussing policy. For large-scale 
projects and the expected return of various genetic information, consider, when necessary, 
requesting the assistance of external experts during the policy discussion stage.  
 When deciding policy that does not plan to ROGRR, as a result of the aforementioned 
considerations, ensure that the policy is in line with the JEGHG. This will include providing 
a clear explanation of why the results will not be returned on the IC form. 
 The ROGRR policy should be approved by an Institutional Review Board. 
2) Points to consider for detailed discussion on ROGRR 
(1) Persons eligible for ROGRR 
 It is important to keep in mind that some features of ROGRR differ from clinical 
situations that provide healthcare with genetic testing included. These features include 
the fact that research participants may not develop the specific disease being as research 
target (ROGRR may include unexpected findings for research participants), 
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considerable time may elapse between providing IC and ROGRR, opportunities to 
make contact with researchers are limited, and it may be difficult to collect information, 
such as medical history and family history, in advance.  
 When research participants are obviously biologically related in Trio analysis and 
etcetera, give due consideration of the return process and heed particular attention to 
participants’ “right not to know” among those that do not wish for ROGRR. This may 
entail providing an appropriate explanation of the nature of genetic information sharing 
among relatives while IC intentions are confirmed for ROGRR. 
 If research participants pass away by the time the ROGRR is ready, please carefully 
consider whether to return the results to the family of the deceased (biological relatives), 
while taking account of the characteristics of the genetic information being returned. If 
a policy allows ROGRR to family of the deceased (biological relatives), it is important to 
carefully consider aspects of the return process, including whether the deceased 
participant wishes the information to be returned to his/her family of the deceased 
(biological relatives) after death, and which family of the deceased (biological relatives) 
will receive the information. 
 If proxy consent is needed for research participants who, for example, has dementia or 
who is a minor, carefully consider policy following the JEGHG.  
(2) Types of genetic information planned to return 
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 Examine what kind of genetic information can be returned. Candidates for ROGRR 
include primary findings (discovered in the research process) and secondary findings 
(entailing the targeted detection of variants). Carefully consider the accuracy and 
reliability of the candidate genetic information. When planning to return the 
information with uncertainty about accuracy or reliability necessarily, researchers 
should be mindful of the possible misunderstanding or psychological stress that may 
emerge in research participants.  
 Carefully consider whether the candidate genetic information returned may lead to 
carrier status or pre-symptomatic testing in participants and whether such information 
should be included for return. In the case that it is included, cautiously consider 
planning a return process that accommodates the potential medical and psychological 
impact on participants.  
 Carefully assess the potential impact that returning candidate genetic information could 
have on research participants post-return and responses that could be anticipated based 
on the information at hand. In particular, when anticipating the return of pathogenic 
variants related to monogenic diseases (including multifactorial diseases with a clear 
involvement of specific genes), collect and evaluate any information related to the 
analytical validity, clinical validity, and clinical utility of the diseases. It is also highly 
recommended that physicians with extensive medical experience with the disease and 
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experienced genetic counselors are involved in any deliberation and a system that allows 
the procurement of advice in advance is established. Specific points are illustrated in the 
subsequent paragraphs.  
 Consider whether the analytical validity of the candidate genetic information can be 
confirmed. It is important to verify whether there are available laboratories for 
confirmation testing as a clinical testing laboratory, because this process is also relevant 
to situations where genetic testing of biological relatives is conducted after ROGRR.  
 It is important to consider the method of variant interpretation and kind of variants to 
be returned when assessing the clinical validity of the candidate genetic information. It 
also particularly important to consider the variant interpretation process when 
information regarding the phenotype of research participants is limited; for example, in 
population-based research or when there are potential non/pre-symptomatic 
participants present.  
 When evaluating the clinical utility of the candidate genetic information, carefully 
consider, in addition to medical care following the return (e.g., treatment and 
prevention), whether medical care for the disease is provided in the healthcare system 
(including descriptions of medical practice guidelines) and the accessibility of medical 
institutions to participants. It is particularly important to carefully consider whether 
follow up is available with/without public insurance post-return, in which there is a 
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possibility of returning the candidate genetic information to pre-symptomatic 
participants. 
(3) Ensuring systems to facilitate ROGRR as a research project 
 The systems required for ROGRR vary depending on the scale of the research, the 
genetic information to be returned, and its disease frequency. Consider whether it is 
possible to ensure that there will be systems in place that respond appropriately to 
inquiries from research participants during the ROGRR process, including whether the 
researchers themselves will respond and/or the provision of opportunities for genetic 
counseling. When necessary, ensure a system that provides access to professional 
support for genetic counseling, including clinical geneticists and certified genetic 
counselors.  
 As research participants may need medical care after ROGRR, especially in the case of 
research conducted at institutes not affiliated with medical institutions and research 
that targets healthy people and the general population, it is desirable to consider in 
advance which medical institutions participants could be referred to.  
 Consider in advance who will pay for the expenses related to medical care after ROGRR, 
such as genetic counseling, confirmation testing, and responses to biological relatives, 
while bearing in mind that expenses may be high. 
 Please consider beforehand the response for requests to disclosures related to genetic 
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information that the project was not expected to return. 
 
3. IC and confirmation of preference for ROGRR  
 For the IC process of the research, consider what kind of information will be communicated 
concerning ROGRR, including the content detailed in the IC documents. Take full account of 
the fact that confirming the preference for the return of specific genetic information may later 
lead to the delivery of unexpected information to research participants. Reflect on a return 
process that is conscious of the potential psychological impact, especially when detailed 
information is not provided on the genetic information expected in the ROGRR during IC. 
Moreover, give full consideration to the fact that time may pass from the point of IC to ROGRR, 
as stated previously. 
 Consider the content of the IC documents including the differences from clinical testing, the 
expected period until the return, and the fact that there are various limitations on ROGRR. In 
particular, when the patients participate in research at a medical institution, pay close attention 
to the possibility that the participants may perceive ROGRR as clinical testing.  
 The opportunities to confirm the intentions of research participants for ROGRR vary depending 
on the project. Fully reflect on the fact that it will be possible to confirm intentions for ROGRR 
in more detail.  
 It is important to adopt more careful methods of identification when obtaining IC and 
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confirming of the intentions for ROGRR. Consider what method will be used to confirm identity 
beforehand depending on the method of communication with research participants (e.g., 
face-to-face, telephone, or written communication). 
 When confirming intentions for ROGRR, it is important to ensure research participants of their 
“right not to know.” However, carefully consider the content and methods used to allow research 
participants to make an informed choice based on their full understanding, particularly when 
genetic information being potentially returned has extremely high clinical utility and failure to 
inform such information would be life-threatening. 
 
4. Analysis related to information with possibility of return  
1) Quality control and confirmation testing  
 Depending on the research, the intended findings vary, including specific variants of 
individuals and statistical trends in groups, and so the quality of analysis required varies 
accordingly. Consider the methods of quality control during analysis in conjunction with the 
confirmation testing described below (based on the research purpose and content).  
 Carefully consider the method and timing of confirmation testing beforehand, particularly 
when it is expected that results being returned may or will be used in clinical settings, 
including the re-collection of samples and re-analysis of them at a clinical laboratory using a 
quality assurance system designed for clinical genetic testing; full consideration should be 
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given to the risks, such as limits on the accuracy of the analytic methods, sample mix-ups 
due to de-identification, and human error. It is desirable to consider such things in advance, 
in conjunction with the system used for providing genetic testing when biological relatives 
request testing following ROGRR.  
2) Process for variant interpretation 
 Implement the process of identifying candidate variants and interpreting their significance 
after carefully considering the specific procedure and system selected beforehand, including 
the use of reference databases and convening expert panels for interpretation.  
 When returning results in situations characterized by limited opportunities to collect 
information on the phenotypes of the research participants beforehand, for example, in 
research that targets the general population and the return of secondary findings, careful 
consideration may be needed regarding the collection of information on clinical symptoms 
and family history and the use of re-assessment by experts. 
 Even when outsourcing analysis, including variant interpretation, to an external institution, 
such as a registered clinical laboratory, results should be returned only after fully considering 
and re-interpreting the results by research project.  
 Consider the possibility of re-analysis and re-interpretation after ROGRR based on the 
information to be returned and the research purpose and content. In addition, when results 
are returned to participants, please ensure an opportunity to provide an explanation 
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alongside a discussion of the limitations of such testing.  
 
5. Return of results to research participants who prefer to receive the genetic information 
1) Process of ROGRR  
 When the preparations for returning genetic information are ready, re-confirm the intent of 
the research participants. In situations that did not provide detailed candidate genetic 
information beforehand, fully consider the procedure that may be involved in re-contacting 
research participants to ensure their “right not to know.” At this point, it is also desirable to 
consider the response policy given to research participants that do not request return or 
request postponing ROGRR beforehand. 
 Confirm the understanding and memory of research participants and explain essential 
concepts again, as necessary, before ROGRR because the research participants will not 
recall details on ROGRR due to factors like the passage of time since their enrollment in 
research.  
 When ROGRR, fully consider the fact that it may be difficult to collect information that 
causes ROGRR related psychological stress, such as social situations, including life events 
and the health condition of research participants; this is particularly pertinent for research in 
non-medical institutions. For research that conducts genome-wide analysis, fully consider 
the possibility that unexpected results may be returned to research participants. 
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Furthermore, please ensure that the research participants are informed in advance by 
including a description in IC documents that details the possibility of social disadvantage, 
such as genetic discrimination for ROGRR because of the lack of legal prohibition of genetic 
discrimination in Japan. 
 Reflect on the return procedure that will be used (e.g., face-to-face, telephone, or written 
communication) as well as the explanatory content that will be included, depending on the 
type of genetic information and the particular circumstances of research participants. 
Substantively consider their privacy and the possibility of inducing psychological stress. In 
particular, it is desirable that the genetic information that indicates the risk of developing 
disease (e.g. monogenic diseases) is returned face-to-face in a place where privacy is 
ensured. When returning information related to health, please ensure the involvement of 
professionals, such as clinical geneticists, certified genetic counselors, and experts on the 
particular disease for the point of ROGRR, and implement the process of making genetic 
counseling available when necessary. 
 Explain the characteristics of returning of research analysis results, that is not equivalent to 
clinical testing, as well as their limitations in comprehensible terms for research participants. 
Depending on the circumstances, also inform research participants that ROGRR and 
genetic testing related to such information is an advanced or innovative approach at present. 
In particular, when returning a negative genetic result of a disease, carefully explain the 
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need to continue with healthy behavior, such as going for a health checkup and medical 
treatment, rather than ignoring or dismissing the possibility of a high risk of developing a 
disease.  
 Even when ROGRR is employed face-to-face and by phone, it is desirable that documents 
that include the results and explanatory matters written in an understandable form are 
delivered to the research participants. Consider the possibility that other family members 
will also receive the results from the same project and prepare the report with his or her 
name on it, so the relevant participants will know that which report is their own.  
2) Records related to ROGRR  
 It is desirable to retain records related to ROGRR including subsequent referrals to medical 
institutions for a certain period while anticipating being contacted by research participants. 
In addition, consider the method of record keeping within the research project in advance 
and have taken measures to prevent any leakage of information. 
3) Follow up 
 When referring research participants to medical institutions, carefully provide an 
explanation of the specific details related to visiting a medical institution, including the 
expected procedures and approximate expenses for the research participant involved, after 
sharing sufficient information with the medical institution in the referral beforehand.  
 Keep in mind that not all research participants that receive results will be continuously 
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engaged with a medical institution, particularly when negative genetic results (such as no 
detection of significant genetic variants) are also included in the scope of the return. For 
most of the projects, though the research duration is limited, and it is desirable to provide a 
helpline to respond to contacts from research participants for a certain period after ROGRR. 
Also, reflect on the response following the end of the project period in advance. 
 
 
Discussion 
We proposed the first Japanese practical guidance for ROGRR. In Japan, there are few reports that 
have implemented ROGRR, particularly in large-scale genome research (16,17), and it is anticipated in the 
future that many research projects will consider ROGRR carefully and realistically. To our knowledge, 
there are few cases such as our collaborative work with various experts regarding genomic research and 
healthcare and researchers specialized in ethical, legal, and social implications. Additionally, in the process 
of drafting the practical guidance above described, we found various issues that require continuous 
discussion and engagement. Those that are particularly important are listed below. 
First, it is fundamentally important to pursue continuous efforts related to enhancing genomic 
medicine delivery systems. Japan’s health care system is characterized by access to advanced medical care 
at a low cost to patients owing to the universal insurance system that provides all citizens with public 
health insurance (18). However, insurance often does not cover treatment options such as genetic testing, 
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genetic counseling, and medical care; especially in surveillance and preventive treatments of 
pre-symptomatic individuals. For example, only 79 diseases are currently covered by insurance in Japan, 
while preventive management of hereditary breast and ovarian cancer syndrome, such as risk-reducing 
salpingo-oophorectomy and risk-reducing mastectomy, are only available at limited medical institutions 
and are not covered by insurance. The results of interviews with stakeholders suggested that this situation 
could represent an obstacle that may hamper the current positive perceptions of ROGRR carried out by 
researchers. It is important that personalized treatment and prevention based on genetic information be 
evaluated from multiple perspectives (e.g., medical economics or patient advocacy). Continued discussion 
on the medical care delivery system, including public insurance coverage, should be encouraged. It is 
necessary to direct existing efforts to develop systems that cater for large number of people who require 
genomic medicine and can provide access to appropriate treatment and prevention, beyond the issues 
related to ROGRR. 
The second issue is the need to provide ROGRR support systems for researchers. In the research 
that ROGRR is not included in the original protocol, researchers have to make extra efforts when putting 
ROGRR into practice. Especially if the research is conducted by non-medical professional researchers or 
institutes without any related hospital, there may be more difficulties on ROGRR. In particular, when 
genetic information outside of the researchers’ expertise is selected as the target for the return, the 
process of interpreting pathogenic variants that require accuracy and reliability as well as referral to a 
clinical specialist, is a burden for researchers. If there will be actionable genetic information that is 
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frequently returned, it is necessary to consider what efforts can be carried out to reduce the burden on 
researchers, including outsourcing processes related to the detection and determination of pathogenic 
variants, the creation of tailored results reports for entities external to the research project (19), and the use 
of medical institutional networks involved in genomic medicine.  
The third pertinent issue is the expense associated with ROGRR. When implementing ROGRR, it 
is necessary to secure the expense budget required to conduct confirmation testing, re-contact research 
participants, and return their results, especially in the case of secondary use of stored samples and 
information. However, in our interviews of researchers, some of them stated that it is difficult to figure out 
whether it is possible to include expenses related to ROGRR into their budget, particularly in the research 
where ROGRR is not included in the original protocol. Much research that accompanies large-scale 
genome analysis in Japan is conducted using grants predominantly funded by government agencies. We 
consider the guidance provided by said funding agencies regarding ROGRR and distinct policy on its 
implementation in the budget would help researchers that think ROGRR is possible within their 
framework and technology.  
In preparing this practical guidance, we conducted interviews with Japanese stakeholders, 
collected comprehensive information in Japan and overseas by conducing literature reviews, and 
attempted to propose a practical guidance that aligns with the current state of affairs in Japan. However, 
there are some limitations. We could not collect enough previous cases with ROGRR because we searched 
only published articles. The interviews had a small sample size with election method bias. Moreover, we 
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compiled the guidance with a focus on the points to consider from the perspectives concerned with the 
ethical, legal, and social implications of ROGRR, and we could not treat some specific details, such as 
proxy consent and non-return policy. In the future, it is hoped that consideration regarding the practical 
guidelines on such matters like quality control will be advanced through expert-centered discussions. 
Under the current government’s JEGHG, in principle, researchers requested to keep genetic information 
as de-identified data, and there is no description on how to manage such information for ROGRR. Given 
the possibility that genetic information returned is used in clinical practice and shared with biological 
relatives, we think that research projects have to respond to the inquiries from research participants at 
least for a while. On the other hand, it may raise another concern about protecting such personal 
information. We think that stored genetic information in a re-linked state with personal information 
should be kept to a limited. We should discuss how we should store such information for ROGRR 
especially when it is conducted on a large scale.  
It is necessary to continuously discuss the problems related to ROGRR in the context of Japan’s 
genomic research and medicine practices, particularly regarding ethical, legal, and social implications. 
Moreover, we believe these discussions and considerations by various stakeholders, including research 
participants, researchers, and national government agencies, can contribute to creating a new system that 
will allow personalized medicine and prevention using genetic information to become more familiar and 
useful to the general population. 
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Figure Legends 
Figure 1 Return of Individual Genomic Information in Research Settings (ROGRR): Flowchart for 
preliminary review before discussion on policy 
 Table 1 Scope of applications and targets of major laws and guidelines 
Name 
Established 
Year 
Latest 
Revision 
Major scope of applications and targets 
Act on the Protection of Personal Information 
2003 2019 
Private business operator handling personal 
information 
Act on the Protection of Personal Information Held by 
Administrative Organs 
2003 2019 
State administrative organs 
Act on the Protection of Personal Information Held by 
Incorporated Administrative Agencies 
2003 2019 
Incorporated administrative agencies 
Ordinances for the Protection of Personal Information Held 
by Local Governments 
- - 
Local governments 
Fundamental Principles of Research on the Human Genome
（Council for Science and Technology, Bioethics Committee） 
2000 - 
Research on human genome 
Ethical Guidelines for Human Genome/Gene Analysis 2001 2017 Human genome/gene analysis research 
 1) These guidelines were newly established after substantial revision of the previous guidelines which were first enforced by MEXT and MHLW in 
2002.  
MEXT: Ministry of Education, Culture, Sports, Science and Technology, MHLW: Ministry of Health, Labour and Welfare, METI: Ministry of Economy, 
Trade and Industry 
Research（MEXT, MHLW, METI） 
Ethical Guidelines for Medical and Health Research Involving 
Human Subjects（MEXT, MHLW） 2014 2017 
Medical and health research involving human subjects 
which is carried out by a Japanese research institution 
or carried out in Japan.  
Guidelines for clinical research of gene therapy（MHLW） 2002 2019 Clinical research of gene therapy1) 
Table 2 Classified points of interest based on interviews summary 
Main theme Sub theme 
1. Overview of research projects and current status 
of ROGRR 
 
2. Experiences and opinions about ROGRR 
1) Determination of policy on ROGRR 
 
 
 
 
 
 
 
 
2) Analysis related to information with possibility 
of return 
 
3) ROGRR to research participants 
 
 
4) Issues to be addressed by all stakeholders 
 
(1) research purpose and content   
(2) systems and background on determination of policy 
(3) research participants, numbers, situation eligible for ROGRR 
(4) types of genetic information planned to return 
(5) IC and confirmation of preference for ROGRR 
(6) actual methods and systems on ROGRR 
(7) cost and human resources   
(8) response for requests to disclosures 
 
(1) quality control (2) interpretation (3) re-identification (4) confirmation testing 
 
 
(1) results report (2) retaining records related to ROGRR (3) information to explain 
(4) follow up 
 
(1) establishing guidelines (2) coordinating among stakeholders 
(3) progress of medical research and healthcare (4) data sharing 
Figure 1 Return of Individual Genomic Information in Research Settings (ROGRR) : Flowchart for preliminary review before discussion on policy
 This flowchart is a summary of points that should be reviewed before a discussion of policy on ROGRR. 
 Among ROGRR, target cases of the research are those with the possibility of returning germline genetic information. 
 Depending on the type of information returned, ROGRR could lead to the genetic testing and the diagnosis of research participants and their biological relatives. Therefore, it is necessary to consider the 
characteristics of genetic information with appropriate gravity and just as carefully as genetic testing and diagnosis in clinical practice.
 When planning the contents and method of return actually, fully consider the details with reference to not only this flow chart and text but also the relevant laws and guidelines. 
(1) In the main research purpose and content, ROGRR will be
included not included
Consider the content and method of ROGRR
(2) The samples and information for analysis will be
newly obtained already obtained
(3) In the consent obtained, ROGRR is
possible not included
(4) Obtaining returnable genetic information will be
expected not expected
(5) Securing the expenses and human resources required for ROGRR will be
available unavailable
(6) Observing the related guidelines for ROGRR will be
possible difficult
The research that ROGRR is included in the main research purpose and content is assumed to the following examples
 The case of returning information on relevant variant in interventional research using the results of genome analysis to
determine the administration of medication.
 The case of returning genetic information to evaluate the return process and psychosocial aspects.
If genome-wide analysis such as whole genome/exome analysis is planned, it is desirable to
“expect,” the possibility of ROGRR regardless of whether there are plans to detect variants out
of on the research purposes. It is also important to consider preparing a framework for ROGRR.
Review the points to be requested when determining policy presented in government’s Ethical Guidelines for
Human Genome/Gene Analysis Research, with due consideration of whether the genetic information is
accurate and reliable for its use as information for assessing the donor’s health condition; whether the
genetic information indicates important facts related to his or her health; and whether the disclosure of the
genetic information could hinder the appropriate research procedures.
Carefully consider whether ROGRR is possible, including the following: check with the
supplier regarding issues such as whether the terms of use and contractual content in the
transfer of samples and information or any joint research and accompanying consent with
respect to the possibility of ROGRR. In addition check whether it is possible to reconnect
genome analysis results with individual information, e.g., contact details. Check whether it is
possible to re-contact research participants regarding ROGRR.
consider not returning
consider not returning
consider not returning
consider not returning
Consider whether it is actually possible for the research to secure the expenses for
necessary analyses which may include confirmation testing and a system that can
provide genetic counseling when needed.
Supplementary Table 1: Overview of the literature review of previous studies on ROGRR 
Projects (institutions) Country Articles 
ABiM biobank cohort (Lund University) Sweden Nilsson MP et al., 2018(1) 
Estonian Biobank (University of Tartu) Estonia Leitsalu L et al., 2016(2) 
MyCode Community Health Initiative 
(Geisinger Health System) 
U.S. Faucett WA et al., 2016(3) 
ClinSeq study(CSER)  
(National Human Genome Research Institute) 
U.S. Lewis et al., 2016(4) 
MedSeq Project(CSER) 
(Brigham and Women's Hospital, Harvard Medical School) 
U.S. Christensen KD et al., 2016(5) 
Cirino AL et al., 2017(6) 
NextGen Study(CSER) 
(Kaiser Permanente Northwest) 
U.S. Korngiebel DM et al., 2016(7) 
Kauffman TL et al., 2017(8) 
Kauffman TL et al., 2017(9) 
eMERGE Study (Northwestern University) U.S. Hylind R et al., 2018(10) 
HealthSeq project 
(Icahn School of Medicine at Mount Sinai) 
U.S. Sanderson SC et al., 2016(11) 
CAGI4 SickKids clinical genomes challenge 
(University of Maryland) 
U.S. Pal LR et al., 2017(12) 
HudsonAlpha study(CSER) 
(University of Louisville) 
U.S. Brothers KB et al., 2017(13) 
NCGENES study(CSER) 
(University of North Carolina at Chapel Hill) 
U.S. Rini C et al., 2018(14) 
SickKids Genome Clinic 
(The Hospital for Sick Children) 
Canada Bowdin SC et al., 2016(15) 
Anderson JA et al., 2017(16) 
Mendel study 
(Baylor-Hopkins Center for Mendelian Genomics) 
U.S. Fiallos K et al., 2017(17) 
- (Cincinnati Children's Hospital Medical Center) U.S. Myers MF et al., 2017(18) 
100,000 Genomes Project (University of Oxford) England Ormondroyd E et al., 2018(19) 
CanSeq study(CSER) (Dana-Farber Cancer Institute) U.S. Gray SW et al., 2016(20) 
Ghazani AA et al., 2017(21) 
NEXT Medicine Study(CSER) (University of Washington) U.S. Goodman JL et al., 2017(22) 
IMAC Study (National University Cancer Institute) Singapore Heong V et al., 2018(23) 
MASTER 
(National Center for Tumor Diseases (NCT) Heidelberg) 
Germany Horak P et al., 2017(24) 
ASPREE Healthy Ageing Biobank (Monash University) Australia Lacaze P et al., 2017(25) 
Lausanne Institutional Biobank 
(CHUV University Hospital) 
Swiss Bochud M et al., 2017(26) 
TMM (Tohoku University, Iwate Medical University) Japan Yamamoto K et al., 2017(27) 
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